The newly-launched program, led by Canadian non-profit TheraPsil, is the world’s largest medical psilocybin access and data project VANCOUVER, BC, July 28, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical-stage natural psychedelic drug development company, today announced its participation in Project Solace, the world’s largest…


Previous articlePT342 – Spencer Hawkswell – The Right to Psilocybin in Canada: TheraPsil’s Charter Challenge
Next articleAlgernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough